CAPR
NASDAQ
$27.34
Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $54.11 (+97.92%)
Market Cap
$1.68B
EPS 5Y CAGR
+22.65%
FCF 5Y CAGR
+50.90%
Free Cash Flow Yield
-5.94%
Price Chart
Valuation
Market Cap$1.68B
Forward P/E78.74
P/S124.43
P/B6.10
Profitability
Gross Profit (TTM)-$93M
EBITDA-$118M
Profit Margin-63.9%
Operating Margin-69.1%
EPS-$2.22
Financial Health
Free Cash Flow Yield-5.94%
Growth & Risk
EPS 5Y CAGR+22.65%
FCF 5Y CAGR+50.90%
Beta (5Y)1.46
Sharpe Ratio0.96